4.4 Article

The Toxin-Producing Pathobiont Klebsiella oxytoca Is Not Associated with Flares of Inflammatory Bowel Diseases

期刊

DIGESTIVE DISEASES AND SCIENCES
卷 60, 期 11, 页码 3393-3398

出版社

SPRINGER
DOI: 10.1007/s10620-015-3765-y

关键词

Klebsiella oxytoca; IBD; MLST; Toxin

资金

  1. Oesterreichische Nationalbank [14321]
  2. Austrian Science Fund (FWF) [W 901] Funding Source: researchfish

向作者/读者索取更多资源

Alterations in the intestinal microbiota are thought to be involved in the pathogenesis of inflammatory bowel diseases (IBD). Klebsiella oxytoca is an intestinal pathobiont that can produce a cytotoxin (tillivaline). We aimed to elucidate the pathogenetic relevance of toxin-producing K. oxytoca in patients with IBD flares and investigated the clonal relationship of K. oxytoca isolates from IBD patients using multilocus sequence typing (MLST). Fecal samples of 235 adult IBD patients were collected from January 2008 to May 2009 and were tested for K. oxytoca, C. difficile toxin, and other pathogens by standard microbiological methods. Clinical data and disease activity scores were collected. K. oxytoca isolates were tested for toxin production using cell culture assays. A total of 45 K. oxytoca isolates from IBD patients, healthy, asymptomatic carriers and from patients with antibiotic-associated hemorrhagic colitis in part from our strain collection were tested for their clonal relationship using MLST. The prevalence of K. oxytoca in IBD overall was 4.7 %. Eleven K. oxytoca isolates were detected. Two of 11 isolates were tested positive for toxin production. There was no significant difference in the distribution of K. oxytoca isolates between the groups (active vs. remission in UC and CD). MLST yielded 33 sequence types. K. oxytoca isolates from IBD did not cluster separately from isolates from asymptomatic carriers. Our data demonstrate that toxin (tilivalline)-producing K. oxytoca is not associated with IBD flares.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Toxin-Producing Klebsiella oxytoca in Healthy Infants: Commensal or Pathobiont?

Theresa M. Greimel, Laura Stampfer, Eva Leitner, Sabine Kienesberger, Ellen L. Zechner, Michael Bozic, Gabriel E. Wagner, Katrin Unterhauser, Maksym Kitsera, Almuthe C. Hauer, Gregor Gorkiewicz, Philipp Wurm, Francesco Valitutti, Christoph Hogenauer, Karl Martin Hoffmann

Summary: Over 70% of healthy infants were found to be colonized with K oxytoca, but toxin levels were below detection level and only half of the isolates produced toxin in vitro. This has important implications for future disease association studies.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2022)

Article Microbiology

Bacterial Indole as a Multifunctional Regulator of Klebsiella oxytoca Complex Enterotoxicity

Nagender Ledala, Mishika Malik, Karim Rezaul, Sara Paveglio, Anthony Provatas, Aaron Kiel, Melissa Caimano, Yanjiao Zhou, Jonathan Lindgren, Kristyna Krasulova, Peter Illes, Zdenek Dvorak, Sandhya Kortagere, Sabine Kienesberger, Amar Cosic, Lisa Poeltl, Ellen L. Zechner, Subho Ghosh, Sridhar Mani, Justin D. Radolf, Adam P. Matson

Summary: In this study, it was shown that bacterial indole acts as a multifunctional mitigator of pathogenicity by suppressing toxin production, enhancing conversion of tilimycin to tilivalline, and activating PXR.
Article Medicine, General & Internal

COVID-19 Pulmonary Pathology: The Experience of European Pulmonary Pathologists throughout the First Two Waves of the Pandemic

Francesco Fortarezza, Federica Pezzuto, Paul Hofman, Izidor Kern, Angel Panizo, Jan von der Thuesen, Sergei Timofeev, Gregor Gorkiewicz, Sabina Berezowska, Laurence de Leval, Cristian Ortiz-Villalon, Francesca Lunardi, Fiorella Calabrese

Summary: Autoptic studies of patients who died from COVID-19 are crucial for improving our understanding of the disease and its impact on patient management and treatment.

DIAGNOSTICS (2022)

Article Hematology

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

Francesco Marchesi, Jon Salmanton-Garcia, Ziad Emarah, Klara Piukovics, Marcio Nucci, Alberto Lopez-Garcia, Zdenek Racil, Francesca Farina, Marina Popova, Sofia Zompi, Ernesta Audisio, Marie-Pierre Ledoux, Luisa Verga, Barbora Weinbergerova, Tomas Szotkovski, Maria Gomes Da Silva, Nicola Fracchiolla, Nick De Jonge, Graham Collins, Monia Marchetti, Gabriele Magliano, Carolina Garcfa-Vidal, Monika M. Biernat, Jaap Van Doesum, Marina Machado, Fatih Demirkan, Murtadha Al-Khabori, Pavel Zak, Benjamfn Vfsek, Igor Stoma, Gustavo-Adolfo Mendez, Johan Maertens, Nina Khanna, Ildefonso Espigado, Giulia Dragonetti, Luana Fianchi, Maria Ilaria Del Principe, Alba Cabirta, Irati Ormazabal-Velez, Ozren Jaksic, Caterina Buquicchio, Valentina Bonuomo, Josip Batinic, Ali S. Omrani, Sylvain Lamure, Olimpia Finizio, Noemf Fernandez, Iker Falces-Romero, Ola Blennow, Rui Bergantim, Natasha Ali, Sein Win, Jens Van Praet, Maria Chiara Tisi, Ayten Shirinova, Martin Schoenlein, Juergen Prattes, Monica Piedimonte, Verena Petzer, Milan Navratil, Austin Kulasekararaj, Pavel Jindra, Jiff Sramek, Andreas Glenthoj, Rita Fazzi, Cristina De Ramon-Sanchez, Chiara Cattaneo, Maria Calbacho, Nathan C. Bahr, Shaimaa El-Ashwah, Raul Cordoba, Michaela Hanakova, Giovanni Paolo Maria Zambrotta, Giovanni Zambrotta, Mariarita Sciume, Stephen Booth, Raquel Nunes Rodrigues, Maria Vittoria Sacchi, Nicole Garcia-Pouton, Juan-Alberto Martin-Gonzalez, Sofya Khostelidi, Stefanie Graefe, Laman Rahimli, Emanuele Ammatuna, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Nikolai Klimko, Philipp Koehler, Antonio Pagliuca, Francesco Passamonti, Oliver A. Cornely, Livio Pagano

Summary: Patients with acute myeloid leukemia (AML) who are diagnosed with COVID-19 are at high risk of death. The management of AML patients with COVID-19 has not been established. In our study, a significant number of AML patients receiving or having received AML treatment had severe or critical COVID-19. Chemotherapy was modified or discontinued in a substantial portion of patients. The mortality rate was high, and survival was better when AML treatment could be delayed.

HAEMATOLOGICA (2023)

Article Gastroenterology & Hepatology

Methanogenic archaea in the human gastrointestinal tract

Christoph Hoegenauer, Heinz F. Hammer, Alexander Mahnert, Christine Moissl-Eichinger

Summary: Archaea, as a part of human gut microbiota, play an important role in human health and disease. However, their significance remains largely unknown due to their non-bacterial biology and detection issues.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2022)

Article Medicine, General & Internal

Tofacitinib in the treatment of ulcerative colitis A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (oGGH)

Maximilian Kutschera, Gottfried Novacek, Walter Reinisch, Christoph Hoegenauer, Wolfgang Petritsch, Thomas Haas, Alexander Moschen, Clemens Dejaco

Summary: This paper summarizes the mechanism, clinical development, efficacy, and safety of tofacitinib, and aims to optimize its safe and effective use in daily clinical practice.

WIENER KLINISCHE WOCHENSCHRIFT (2022)

Article Gastroenterology & Hepatology

Fungal translocation measured by serum 1,3-β-D-glucan correlates with severity and outcome of liver cirrhosis-A pilot study

Matthias Egger, Angela Horvath, Florian Prueller, Peter Fickert, Malcolm Finkelman, Lisa Kriegl, Henning Gronbaek, Holger Jon Moller, Juergen Prattes, Robert Krause, Martin Hoenigl, Vanessa Stadlbauer

Summary: Liver cirrhosis, a systemic disease causing 1 million deaths per year, is associated with fungal translocation and its effects on gut integrity, inflammation, and liver disease severity/outcome. This study found a correlation between fungal translocation and markers of gut inflammation, as well as a significant difference in mortality between patients with positive versus negative fungal translocation. Further research is needed to understand the complex interactions and potential therapeutic interventions.

LIVER INTERNATIONAL (2023)

Article Virology

Multifactorial White Matter Damage in the Acute Phase and Pre-Existing Conditions May Drive Cognitive Dysfunction after SARS-CoV-2 Infection: Neuropathology-Based Evidence

Ellen Gelpi, Sigrid Klotz, Miriam Beyerle, Sven Wischnewski, Verena Harter, Harald Kirschner, Katharina Stolz, Christoph Reisinger, Elisabeth Lindeck-Pozza, Alexander Zoufaly, Marlene Leoni, Gregor Gorkiewicz, Martin Zacharias, Christine Haberler, Johannes Hainfellner, Adelheid Woehrer, Simon Hametner, Thomas Roetzer, Till Voigtlaender, Gerda Ricken, Verena Endmayr, Carmen Haider, Judith Ludwig, Andrea Polt, Gloria Wilk, Susanne Schmid, Irene Erben, Anita Nguyen, Susanna Lang, Ingrid Simonitsch-Klupp, Christoph Kornauth, Maja Nackenhorst, Johannes Klaeger, Renate Kain, Andreas Chott, Richard Wasicky, Robert Krause, Guenter Weiss, Judith Loeffler-Rag, Thomas Berger, Patrizia Moser, Afshin Soleiman, Martin Asslaber, Roland Sedivy, Nikolaus Klupp, Martin Klimpfinger, Daniele Risser, Herbert Budka, Lucas Schirmer, Anne-Katrin Probstel, Romana Hoeftberger

Summary: We conducted a neuropathological analysis on 32 patients who died from COVID-19 in Austria between 2020 and 2021. The results showed diffuse white matter damage and microglial activation in all cases, indicating indirect brain damage rather than direct virus-specific damage. Inflammatory changes and vascular pathologies were also observed, along with silent neurodegenerative pathologies in elderly patients. These findings align with experimental data on SARS-CoV-2-related brain damage and provide a better understanding of the mechanisms underlying neurological symptoms after COVID-19.

VIRUSES-BASEL (2023)

Article Cell Biology

Microbiota-derived genotoxin tilimycin generates colonic stem cell mutations

Lisa Poltl, Maksym Kitsera, Sandra Raffl, Stefan Schild, Amar Cosic, Sabine Kienesberger, Katrin Unterhauser, Georg Raber, Christian Lembacher-Fadum, Rolf Breinbauer, Gregor Gorkiewicz, Carlos Sebastian, Gerald Hoefler, Ellen L. Zechner

Summary: The DNA-alkylating metabolite tilimycin is a microbial genotoxin that causes colitis in individuals carrying til+ Klebsiella spp. Intestinal stem cells are affected by tilimycin-induced DNA damage, leading to genetic aberrations and increased disease susceptibility in the colon. The presence of tilimycin-producing Klebsiella results in higher frequencies and more mutations per individual compared to non-producing mutants.

CELL REPORTS (2023)

Article Microbiology

COVID-19-Associated Pulmonary Aspergillosis Isolates Are Genomically Diverse but Similar to Each Other in Their Responses to Infection-Relevant Stresses

Matthew E. Mead, Patricia Alves L. de Castro, Jacob L. Steenwyk, Jean-Pierre Gangneux, Martin Hoenigl, Juergen Prattes, Riina Rautemaa-Richardson, Helene B. Guegan, Caroline B. Moore, Cornelia Lass-Floerl, Florian Reizine, Clara Valero, Norman J. Van Rhijn, Michael J. Bromley, Antonis H. Rokas, Gustavo H. Goldman, Sara Gago, ECMM CAPA Study Grp

Summary: Secondary infections caused by Aspergillus fumigatus are a major cause of death in severe COVID-19 patients. Genomic analysis of 11 A. fumigatus isolates from CAPA patients in Europe revealed that CAPA isolates do not cluster based on geographic origin. Phenotypically, CAPA isolates are more similar to the A1160 reference strain, but differ from the Af293 strain in infection-relevant stresses. Further research is needed to understand the molecular epidemiology of CAPA and identify genetic factors contributing to copathogenicity and antifungal resistance in COVID-19 patients.

MICROBIOLOGY SPECTRUM (2023)

Review Dermatology

Questioning the 14-day dogma in candidemia treatment duration

Jon Salmanton-Garcia, Ilana Reinhold, Juergen Prattes, Nico Bekaan, Philipp Koehler, Oliver A. Cornely

Summary: The growing threat of antimicrobial resistance is a global concern, particularly in the treatment of candidemia. The current recommendation of a minimum treatment duration of 14 days for candidemia is being questioned, and further research and clinical trials are needed to establish evidence-based guidelines.

MYCOSES (2023)

Article Cell Biology

Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics

Daniel Podlesny, Marija Durdevic, Sudarshan Paramsothy, Nadeem O. Kaakoush, Christoph Hogenauer, Gregor Gorkiewicz, Jens Walter, W. Florian Fricke

Summary: The study reveals that the coexistence of donor and recipient strains after fecal microbiota transplantation is rare, and the engraftment of donor strains is strongly positively correlated with recipient microbiota dysbiosis. Engraftment of donor strains can be enhanced through antibiotic pretreatment and bowel lavage, and is dependent on the diversity of donor and recipient microbiota.

CELL REPORTS MEDICINE (2022)

Meeting Abstract Pathology

Diagnostic value of ITS sequencing in mucormycosis - a retrospective single-centre study

M. Zacharias, A. Thueringer, K. Kashofer, R. Krause, G. Gorkiewicz

VIRCHOWS ARCHIV (2022)

暂无数据